Julia Blanter

Areas of Expertise

Conditions I Treat

  • Cervical cancers and conditions
  • Ovarian cancers and conditions
  • Uterine cancers and conditions

My Specialties

  • Immunotherapy
  • Early drug development
  • Early-phase clinical trials
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

Get to Know Me

I am a medical oncologist who focuses on the treatment of gynecologic cancers. These include:

I see patients at Memorial Sloan Kettering Monmouth in New Jersey.

My clinical and research efforts are focused on bringing the latest therapies to patients through early-phase clinical trials, especially for women with cancer or disease that is difficult to treat or which keeps returning even after treatment.

My interest in oncology (cancer care) began during college, when a close family member was diagnosed with cancer. This experience—and the dedication of the care team—left a lasting impression on me.

My clinical and research interests center on designing and conducting clinical trials that bring promising new therapies to patients—particularly those with rare or treatment-resistant disease. In addition to being part of the Gynecologic Medical Oncology Service, I am also part of the Early Drug Development Service where I treat patients who are part of clinical trials.

My approach to care is deeply rooted in compassion and partnership. I recognize that a cancer diagnosis adds a significant emotional and logistical burden to my patients’ already demanding lives. My goal is to help each person feel supported and empowered throughout their treatment journey. I aim to offer clear, thoughtful guidance while designing treatment plans that align with each person’s goals, needs, and values.

I work with experts across teams to deliver the latest comprehensive care, while also ensuring access to clinical trials that may expand treatment options. I want my patients to know that I am their advocate and that they are not facing this experience alone.

What I Do at MSK

I'm a gynecologic medical oncologist, which is a cancer doctor who specializes in gynecologic (GY-neh-kuh-LAH-jik) cancers. This includes cervical, fallopian tube, ovarian, uterine (endometrial), vaginal, and vulvar cancers.

I'm an early drug development specialist, which is a scientist who tests new drugs to treat cancer. I have special training in research studies, also known as clinical trials.

  • Assistant Attending Physician
Areas of Expertise

Conditions I Treat

  • Cervical cancers and conditions
  • Ovarian cancers and conditions
  • Uterine cancers and conditions
  • Uterine sarcoma
  • Vaginal cancers and conditions
  • Vulvar cancers and conditions

My Specialties

  • Immunotherapy
  • Early drug development
  • Early-phase clinical trials
This list shows some key areas of focus, but it may not cover all expertise. When making an appointment, you will be matched with the best healthcare provider for your needs.
Education & Honors

Education

  • BS, Brandeis University
  • MS, Brandeis University
  • MD, New York Medical College
  • Master of Science in Clinical Research, Icahn School of Medicine at Mount Sinai

Residencies

  • Internal Medicine, Mount Sinai

Fellowships

  • Hematology/Oncology, Mount Sinai

Awards and Honors

  • Excellence in Leadership and Service Award in the Clinical Research Education Program, Icahn School of Medicine at Mount Sinai (2024)
  • Graduate Medical Education Fellow of the Month Award, Icahn School of Medicine at Mount Sinai (2023)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Learn more about the insurance plans that participate with MSK.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

Health plans can change at any time. Call the number on the back of your insurance card to see what your plan covers. Make sure it covers the MSK location where you’ll get care.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients
Request an appointment by calling your Care Team or messaging them in MSK MyChart.

Contact and Location

Office Phone
Location
Middletown, NJ
480 Red Hill Road Middletown NJ 07748

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Gynecologic Medical Oncology Service doctors

See all Collaborators doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

  1. Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder JP, Galsky MD, Marron TU, Smith CB, LoRusso PM, Hofstatter E, Doroshow DB. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncol Pract. 2025 Jun;21(6):862-875. Epub 2024 Dec 11. PMID: 39661920.
  2. D’Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024 Nov;25(11):1465-1475. Epub 2024 Oct 19. PMID: 39437804; PMCID: PMC12040480.
  3. Landry CA, Blanter J, Ru M, Fasano J, Klein P, Shao T, Bhardwaj A, Tiersten A. Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer. Oncology. 2024;102(1):9-16. Epub 2023 Aug 18. PMID: 37598677.
Publications on PubMed

Visit PubMed for a full listing of Dr. Blanter’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Julia Blanter discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures